Skip to content
TirzepatideReport

Tirzepatide monograph · Evidence review

Ozari Health Tirzepatide Review: Cost, a Checker-Link-Only Claim & Honest Verdict (2026)

An honest 2026 review of Ozari Health tirzepatide — a named legal entity, 503A/503B pharmacy sourcing, and a LegitScript claim with no seal image shown.

Researched & written by Alan Pierce · last updated

Clinical Pharmacology Writer

On this page

Editorial pick

CoreAge Rx

$149/mo flat

Doctor-reviewed tirzepatide with one flat price and built-in human support.

Advertising disclosure · we may earn a commission at no extra cost to you.

Check availability
vs median
$120/mo below the $269 median
Market
$109–$429/mo across 396 providers
Dispensed
Compounded tirzepatide (503A)

Popular alternative

Eden

Compounded tirzepatide at a low headline price, billed on top of a recurring membership.

$199/mo + $99/mo membership

FDA warning letter
FDA issued Eden Health International Inc. dba Eden a warning letter in June 2026 (False & Misleading Claims/Misbranded (Telehealth)). Read the letter on FDA’s own warning-letter database.

Check Eden availability

Ozari Health: its site's own structured data links to a LegitScript checker page, but no LegitScript seal image is displayed anywhere — a weaker signal than a genuine badge, and worth knowing before assuming the certification is fully visible on the site. Every fact here comes from the company's own published program.

This review checked Ozari Health's LegitScript claim directly: the site's structured data references legitscript.com/websites/?checker_keywords=ozarihealth.com, a real checker URL. But this review found no LegitScript seal image displayed anywhere on the page — no badge, no static.legitscript.com-served graphic. The checker link itself is genuine, but the visual certification badge most competitors display isn't present.

§ Ozari Health — Checker Link, No Seal Image

ItemDetail
LegitScript checker linkVerified in structured data; no seal image found
Tirzepatide (month-to-month)$235/mo
Early cancellationRe-prices shipped installments at standard rate
Verified: a genuine checker link exists, but no seal image is displayed anywhere on the site.

What Ozari Health is

Ozari Health is a telehealth weight-loss platform, selling physician-prescribed compounded GLP-1 from licensed 503A and 503B pharmacies, operated by a named entity, Ozari LLC, per its structured data.

What Ozari Health costs

The advertised low rates ($86/month semaglutide) are actually three-month starter plans for first-time GLP-1 users, billed $257 up front for semaglutide. Month-to-month rates are $175 for semaglutide and $235 for tirzepatide. Shipping is included in the plan price.

A real cancellation clawback

Worth flagging directly: canceling an annual or semi-annual plan early re-prices the installments already shipped at the standard monthly rate and charges the difference — a genuine clawback mechanism, not just a forfeited discount.

The brand-vs-compounded question

Ozari Health dispenses compounded semaglutide and tirzepatide, not the FDA-approved branded product. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Ozari Health's real strengths: a named operating entity (Ozari LLC), plus board-certified physicians, 503A and 503B compounding, and shipping included. The trade-offs: this review found no visible LegitScript seal image, only a checker-link reference, the advertised low rates are three-month prepaid starter plans, not ongoing monthly rates, and early cancellation re-prices already-shipped installments at the standard rate and charges the difference. As with any GLP-1 program, and especially a multi-month prepaid plan, confirm the true early-cancellation cost before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-11, and better than semaglutide head-to-head2 — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Ozari Health's named legal entity and 503A/503B sourcing are real positives, but this review found no visible LegitScript badge despite the checker-link claim, and the cancellation clawback on prepaid plans is worth understanding before you sign up for anything longer than month-to-month. For a provider with a genuinely displayed LegitScript seal, compare it against Ondra Health or NewSelf. See our best tirzepatide providers ranking for the full field.

Frequently asked questions

Is Ozari Health's LegitScript certification displayed on the site?

This review confirmed a genuine checker link in the site's structured data, but found no LegitScript seal image displayed anywhere on the page.

How much does tirzepatide cost through Ozari Health?

$235/month month-to-month, or a three-month starter plan billed $375 up front for first-time patients.

What happens if I cancel an Ozari Health plan early?

Already-shipped installments are re-priced at the standard monthly rate and you're charged the difference.

References(2)

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
  2. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Bays HE, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).. New England Journal of Medicine. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/

About the author

Alan Pierce

Clinical Pharmacology Writer

About Tirzepatide Report · How we verify prices · This page last updated August 2026

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Related monograph sections

View all sections